王瑾,汶柯,范贞.药物临床试验中受试者风险管理及基本权益保护[J].中国新药与临床杂志,2015,34(10):748-753.Wang J,Wen K,Fan Z.Risk management and protection of subjects’benefits and rights in drug clinical trials[J].Chin J New Drugs Clin Rem,2015,34(10):748-753.
[2]
夏侠,李媛媛,王坤.药物临床试验风险评估体系建立的初步探讨[J].中国临床药理学杂志,2016,32(8):753-755.Xia X,Li YY,Wang K.Preliminary study on the establishment of drug clinical trial risk assessment system[J].Chin J Clin Pharmacol,2016,32(8):753-755.
[3]
李见明,孙振球,高荣.我国药物临床试验的现状与发展方向[J].中国临床药理学杂志,2013,29(6):473-476.Li JM,Sun ZQ,Gap R.Present situation and development direction of drug clinical trial in China[J].Chin J Clin Pharmacol,2013,29(6):473-476.
[4]
Joshi VD,Oka GA,Kulkarni AA,et al.Public awareness and perception of clinical trials:Quantitative study in pune[J].Perspect Clin Res,2013,4(3):169-174.
[5]
魏豫东,杨丽,张双,等.健康志愿者对临床研究的认知调查[J].中国临床药理学杂志,2014,30(9)828-832.Wei YD,Yang L,Zhang S,et al.Healthy volunteers'knowledge and perception of clinical research[J].Chin J Clin Pharmacol,2014,30(9)828-832.
[6]
Burt T,Dhilon S,Sharma P,et al.PARTAKE survey of public knowledge and perception of clinical research in India[J].PLoS One,2013,8(7):e68666.
[7]
Steinbrook R.Improving protection of research subjects[J].N Engl J Med,2002,346(18):1 425-1 430.
[8]
Adedeji WA,Ibraheem WA,Fehintola FA.Attitude and practice of doctors toward adverse drug reactions(adrs)reporting in a nigerian tertiary health facility[J].Ann Ib Postgrad Med,2013,11(2):77-80.
[9]
Shah JY,Phadtare A,Rajgor D,et al.What leads indians to participate in clinical trials?A meta-analysis of qualitative studies[J].PLoS One,2010,5(5):e10730.
[10]
赵静,王松林,郭冬梅,等.我国药物临床试验机构发展现状分析[J].中国新药杂志,2013,22(4):384.Zhao J,Wang SL,Guo DM,et al.Development situation of drug clinical trial institutions[J].Chinese Journal of New Drugs,2013,22(4):384.
[11]
Joshi V,Kulkayni AA.Public awareness of clinical trials:A qualitative pilot study in Pune[J].Perspect Clin Res,2012,3(4):125-132.
[12]
Yun JC,Sung HB,Woon YK,et al.Knowledge and perception about clinical research shapes behavior:face to face survey in Korean General Public[J].J Korean Med Sci,2016,31(5):674-681.
[13]
王彦荣,李薇,戴欣雅.我院药物临床试验培训存在的问题与对策[J].中国药房,2015,26(1):18-20.WangYR,Li W,Dai XY.Problems of Drug Clinical Trial and Countermeasures in Our Hospital[J].China Pharmacy,2015,26(1):18-20.
[14]
郑君,李义庭.药物临床试验研究者视角下的受试者权益保护情况调查研究——以北京某三甲医院药物临床试验机构的调查研究为例[J].中国新药杂志,2015,24(15):1 754-1 759.Zheng J,Li YT.Research on protection of paticipants'rights and interests in clinical trials:a case study of a clinical trial agency of one 3A grade hospitals in Beijing[J].Chinese Journal of New Drugs,2015,24(15):1 754-1 759.
[15]
陈寅萤,吴萍,王阶.我国药物临床试验机构现状分析[J].中国新药杂志,2014,39(16):3 208-3 210.Chen YY,Wu P,Wang J.Analysis of the present situation of drug clinical trial institutions in China[J].Chinese Journal of New Drugs,2014,39(16):3 208-3 210.
